|
13 July, 2023
|
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
|
|
|
27 June, 2023
|
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
|
|
|
26 June, 2023
|
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
|
|
|
26 June, 2023
|
ICON plc Set to Join Russell 3000® Index
|
|
|
31 May, 2023
|
ICON plc to Attend Upcoming Investor Conferences
|
|
|
16 May, 2023
|
ICON releases its 2022 ICON Cares ESG Report
|
|
|
26 April, 2023
|
ICON Reports First Quarter 2023 Results
|
|
|
29 March, 2023
|
ICON plc Schedules First Quarter 2023 Earnings Conference Call
|
|
|
10 March, 2023
|
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
|
|
|
27 February, 2023
|
ICON plc to Present at Upcoming Investor Conferences
|
|
|
22 February, 2023
|
ICON Reports Fourth Quarter and Full Year 2022 Results
|
|
|
26 January, 2023
|
ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call
|
|
|
10 January, 2023
|
ICON Issues Financial Guidance for Full Year 2023
|
|
|
03 January, 2023
|
ICON plc to Present at the 41st Annual J.P. Morgan Healthcare Conference
|
|
|
13 December, 2022
|
ICON recognised as leading contract research organisation and employer by Scrip, Fierce Life Sciences, Financial Times and others
|
|
|
23 November, 2022
|
ICON plc to Present at the 2022 Evercore ISI HealthCONx Conference
|
|
|
02 November, 2022
|
ICON Reports Third Quarter 2022 Results
|
|
|
06 October, 2022
|
ICON selected by BARDA to conduct anthrax vaccine clinical trial
|
|
|
26 September, 2022
|
ICON plc Schedules Third Quarter 2022 Earnings Conference Call
|
|
|
06 September, 2022
|
ICON Releases its 2021 ESG Report
|
|
